Myasthenia Gravis Market Forecasts to 2028 – Global Analysis By Type (Ocular Myasthenia Gravis, Congenital Myasthenia Gravis, Generalized Myasthenia Gravis, Transient Myasthenia Gravis) and By Geography
According to Stratistics MRC, the Global Myasthenia Gravis Market is accounted for $1.40 billion in 2020 and is expected to reach $3.00 billion by 2028 growing at a CAGR of 10.0% during the forecast period. Factors such as increasing health care spending, improving health care infrastructure, and growing prevalence of autoimmune disorders are driving the growth of the market. However, limited availability of drugs is hampering the growth of the market.
Myasthenia gravis is a chronic autoimmune neuromuscular disorder that is characterized by variable weakness of the voluntary muscle groups. Muscles that observe eye movement, shoulder & facial muscles, breathing & swallowing and eye lids are the ones that are regularly impacted in myasthenia gravis.
Based on the treatment, the drug treatment/medication segment is anticipated to expand at a rapid pace during the forecast period due to the ongoing research and development activities that are being carried out to improve the efficacy of available medications. By geography, North America is going to have high growth during the forecast period as most of the population in the region are covered under medical and health insurance and hence, are able to afford the expensive medication and therapies for myasthenia gravis.
Some of the key players profiled in the Myasthenia Gravis Market include Medtronic Plc., Novartis AG, Koninklijke Philips N.V., F. Hoffmann-La Roche AG, Boston Scientific Corporation, Valeant Pharmaceuticals International, Inc., Pfizer Inc., Baxter International, Inc., Takeda Pharmaceutical Company Limited, Alexion Pharmaceutical Inc., Shire PLC, CSL Behring, Avadel Pharmaceuticals, PLC. (Flamel Technologies), and Grifols S.A.
Estimated Market Size in 2020:
USD 1.40 billion
Compound Annual Growth Rate (CAGR) from 2020 to 2028:
Predicted 2028 Value:
USD 3.00 billion
Tables, Graphs & Figures
Type, Diagnosis, Treatment, End User, and Region
Core Drivers and Opportunities:
Restraining Factors & Market Threats:
• Ocular Myasthenia Gravis
• Congenital Myasthenia Gravis
• Generalized Myasthenia Gravis
• Transient Myasthenia Gravis
• Edrophonium Tests
• Pulmonary Function Tests
• Blood Tests
• Drug Treatment/Medication
• Rapid Immunotherapies
End Users Covered:
• Hospitals & Clinics
• Diagnostic Centers
• Academic & Research Institutes
• North America
o Rest of Europe
• Asia Pacific
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2019, 2020, 2021, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Key Questions Answered In The Report
The Global Myasthenia Gravis Market is majorly driven by the increasing health care spending, improving health care infrastructure, and growing prevalence of autoimmune disorders.
The hospitals & clinics segment is growing at a highest CAGR owing to the large patient pool and in hospital settings and specialty clinics.
North America dominated with a significant market share due to the presence of established research and development facilities.
Asia Pacific market is growing at a highest CAGR owing to the increasing investments in the healthcare sector by the governments and manufacturers in the region.
Key players in Myasthenia Gravis Market include Medtronic Plc., Novartis AG, Koninklijke Philips N.V., F. Hoffmann-La Roche AG, Boston Scientific Corporation, Valeant Pharmaceuticals International, Inc., Pfizer Inc., Baxter International, Inc., Takeda Pharmaceutical Company Limited, Alexion Pharmaceutical Inc., Shire PLC, CSL Behring, Avadel Pharmaceuticals, PLC. (Flamel Technologies), and Grifols S.A.
Select License Type
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.